chronic obstructive pulmonary disease copd
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, caused primarily by smoking-related airflow obstruction and characterized by progressive dyspnea, chronic bronchitis, and exacerbations that drive hospitalizations and mortality. Despite approval of triple inhaled therapy (LABA/LAMA/ICS), exacerbation rates remain high in eosinophilic phenotypes, driving active trials in targeted biological therapies that have transformed severe asthma management.
Active trials investigate dupilumab for eosinophilic COPD (BOREAS and NOTUS trials showed reduced exacerbations), itepekimab (anti-IL-33), tezepelumab (anti-TSLP), mepolizumab for high-eosinophil COPD, phosphodiesterase-3/4 inhibitors, and novel mucolytic approaches. Disease-modifying trials targeting lung regeneration (all-trans retinoic acid, stem cell therapy) and alpha-1 antitrypsin augmentation for AATD-related COPD are also active.
COPD trials typically require post-bronchodilator FEV1/FVC <0.70 with documented history of exacerbations; blood eosinophil count ≥150 or ≥300 cells/μL is increasingly used to enrich biologic trials.
Disease Burden & Epidemiology
Chronic obstructive pulmonary disease (COPD) affects an estimated 480 million people globally β€” approximately 10% of the adult population β€” and is the third leading cause of death worldwide, responsible for approximately 3.2 million deaths annually. In the United States, the CDC estimates that 16 million Americans have a formal COPD diagnosis, though an additional 16 million are estimated to have undiagnosed COPD. COPD is characterized by persistent, largely irreversible airflow limitation caused by airway and alveolar damage, primarily from cigarette smoking, though occupational dust/chemical exposure and indoor air pollution from biomass burning are major causes in non-smoking populations, particularly in low- and middle-income countries. COPD has historically been considered a male disease, but prevalence among women has risen sharply over recent decades β€” women are now equally affected and appear to progress more rapidly with equivalent smoking exposure. Exacerbations β€” sudden worsening of respiratory symptoms requiring medical intervention β€” are the primary driver of hospitalization costs and the strongest predictor of disease progression and mortality. The annual economic cost of COPD in the US exceeds $49 billion in direct medical costs.
Key Research Trends & Landmark Studies
The BOREAS and NOTUS Phase 3 trials for dupilumab in COPD represent the most significant advance in the field in years: dupilumab reduced moderate-to-severe exacerbations by 30% versus placebo in patients with eosinophil counts ≥300 cells/μL, earning FDA approval in 2024 as the first biologic therapy for COPD — a class previously limited to asthma. The IMPACT trial established fluticasone furoate/umeclidinium/vilanterol (Trelegy) triple therapy as superior to dual therapy in reducing exacerbations, establishing triple inhaled therapy as the standard of care backbone. The GALATHEA and TERRANOVA trials evaluated mepolizumab in eosinophilic COPD with mixed results, highlighting the importance of patient selection. The NAVIGATOR trial for tezepelumab in COPD is ongoing. In the lung repair space, the ENaC inhibitor program (STAR trials) targets mucus clearance in chronic bronchitis. The RETHINC trial evaluated roflumilast for the prevention of exacerbations in patients with COPD and chronic bronchitis not receiving ICS, advancing the role of PDE4 inhibition.
Patient Guide: How to Find & Join a Trial
People with COPD can participate in clinical trials at any stage of disease severity, from mild (GOLD 1) to very severe (GOLD 4). The most critical eligibility criteria for most COPD trials are spirometry results β€” specifically the post-bronchodilator FEV1/FVC ratio and FEV1 percent predicted β€” and exacerbation history from the prior 12 months (the number and severity of acute exacerbations determines eligibility for many exacerbation-reduction trials). A blood eosinophil count from a recent complete blood count is increasingly requested at screening for biologic trials. Pulmonology clinics at academic medical centers and large health systems typically have active trial portfolios; many COPD trials are also conducted at community pulmonology and respiratory medicine practices, making geographic access broader than many specialty trials. COPD Foundation (copdfoundation.org) and the Alpha-1 Foundation (for AATD-associated COPD) maintain patient-facing trial finders and support navigation services.